601P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158

Xuan Wu(Tongji University), Jing Xu(Chinese PLA General Hospital), Ming Xu, Yuxian Bai(Harbin Medical University), Yilei Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Huang(Chinese PLA General Hospital), Jing Zhang(Chongqing University), Jianbin Li(Academy of Military Medical Sciences), Dong Wang(Zhejiang Chinese Medical University), Y Deng(Sun Yat-sen University), Jianfeng Yang(Fujian Provincial Hospital), Jianmin Tang(Capital Medical University), Xianli Yin(Central South University), X. Chen(Obstetrics and Gynecology Hospital of Fudan University), Alexander Gozman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nong Xu(First Affiliated Hospital Zhejiang University), Nan-Ping Li
Annals of Oncology
November 1, 2023
10.1016/j.annonc.2023.10.316
Cited by 1

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663